AU1681601A - A method of treating a malignancy in a subject and a pharmaceutical composition for use in same - Google Patents

A method of treating a malignancy in a subject and a pharmaceutical composition for use in same Download PDF

Info

Publication number
AU1681601A
AU1681601A AU16816/01A AU1681601A AU1681601A AU 1681601 A AU1681601 A AU 1681601A AU 16816/01 A AU16816/01 A AU 16816/01A AU 1681601 A AU1681601 A AU 1681601A AU 1681601 A AU1681601 A AU 1681601A
Authority
AU
Australia
Prior art keywords
virus
cells
adhesion molecule
cell adhesion
infectivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU16816/01A
Other versions
AU770517B2 (en
Inventor
Darren R Shafren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viralytics Ltd
Original Assignee
Viralytics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ4256A external-priority patent/AUPQ425699A0/en
Application filed by Viralytics Ltd filed Critical Viralytics Ltd
Priority to AU16816/01A priority Critical patent/AU770517B2/en
Publication of AU1681601A publication Critical patent/AU1681601A/en
Assigned to VIROTARG PTY LIMITED reassignment VIROTARG PTY LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED, THE
Application granted granted Critical
Publication of AU770517B2 publication Critical patent/AU770517B2/en
Priority to AU2004202292A priority patent/AU2004202292B2/en
Assigned to VIRALYTICS LIMITED reassignment VIRALYTICS LIMITED Alteration of Name(s) in Register under S187 Assignors: VIROTARG PTY LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

WO 01/37866 PCT/AUOO/01461 A METHOD OF TREATING A MALIGNANCY IN A SUBJECT AND A PHARMACEUTICAL COMPOSITION FOR USE IN SAME Field Of The Invention 5 The present invention relates to the killing of abnormal cells utilising a virus. There is also described a method of screening cells to ascertain whether they are susceptible to treatment with the virus, as well as pharmaceutical compositions incorporating the virus. The invention finds veterinary use as well as broad application in the human medical field. 10 Background Of The Invention Melanoma is a leading cause of morbidity in the human population. Australia has the highest rate of melanoma in the world. Melanoma is an aggressive skin cancer and is the third most common cancer in Australia for both men and women. It is predicted that one in thirty Australians have a form of melanoma resulting in the death of more than 15 one thousand people per year in that country alone. When detected early most forms of melanoma can be effectively treated. However, the control of more advanced forms is less successful and an area of intensive research. A major goal in this area of research is the identification of molecules that are differentially expressed in benign and malignant melanocytic tumours that can be used for diagnosis and as targets for anti-cancer 20 therapies (Kageshita T. et al; 1993). Intercellular adhesion molecule-I (ICAM-1), a crucial molecule in cellular inflammatory interactions, is an accepted melanoma progression antigen. Surface- WO 01/37866 PCT/AUOO/01461 -2 expression of ICAM- I on melanomas has been highly correlated with malignant melanoma progression (Kraus A. et al; 1997 and Morandini R. et al; 1998). ICAM-1 is a member of the immunoglobulin (Ig) superfamily and a counter receptor for the integrin leucocyte function antigen-1 (LFA-1/CD11 a) and Mac 5 (CD1 Ib), and is a cellular attachment molecule for 90% of human rhinoviruses (Stuanton D.E., et al; 1989). In addition, ICAM-1 plays an important role in the pathogenesis of not only rhinovirus infection, but also in Plasmodiumfalciparum infection and in the exacerbations of asthma, chronic bronchitis and cystic fibrosis. Recently, complement regulatory proteins have been reported to be up-regulated on the 10 surface of malignant melanomas, in particular decay-accelerating factor known as DAF (Cheung NK et al; 1998). Viruses capable of inducing lysis of malignant cells through their replication process are known as oncolytic viruses and trials using oncolytic viruses to treat malignancies have been performed (Nemunaitis J; 1999). Most oncolytic viruses require 15 proliferation in the same species or cell lineage. Infection of a cell by a virus involves attachment and uptake into the cell which leads to or is coincidental with uncoating of the viral capsid, and subsequently replication within the cell (Fenner F., et al. The Biology of Animal Viruses. Academic Press. New York, 1974 Second Ed.) Oncolytic viruses assessed for capacity to kill cancer cells have included the 20 adenovirus subtype Egypt 101 virus which showed oncolytic activity in the HeLa uterine/cervix cancer cell line, mumps virus for treatment of gastric carcinoma, uterine carcinoma and cutaneous carcinoma, Newcastle Disease Virus (NDV), influenza virus for treatment of ovarian cancer, and adenovirus for treatment of for instance, cervical WO 01/37866 PCT/AUOO/01461 -3 carcinoma (Nemunaitis J; 1999). Other reports have indicated that adenoviruses and attenuated poliovirus recombinants may have use in the treatment of malignant glioma cells (Alemany R., et al 1999; Andreansky S.S., 1996), and that reovirus shows lytic capability in human U87 glioblastoma cells and NIH-3T3 cells with an activated Ras 5 signalling pathway (Coffey M.C, et al, 1998; Strong J.E. et al, 1998). In addition, a vaccinia oncolysate has been used in clinical trials to treat melanoma (Stage II) patients (Nemunaitis J., 1999). Modified, non-neurovirulent Herpes simplex viruses (HSV) have also been reported as showing promise for the treatment of brain tumours including intracranial melanoma, and subcutaneous human melanoma 10 (Randazzo B.R., 1997), while adenovirus infection has been reported to enhance killing of melanoma cells by the plant mitotoxin, saporin (Satyamoorthy K., 1997). The receptor on target cells recognised by adenovirus differs for different adenovirus types. That is, adenovirus subgroups A, C, D, E and F for instance recognise the CAR receptor while Adenovirus type 5 (subgroup C), Adenovirus type 2 15 (subgroup C) and Adenovirus type 9 (subgroup D) recognise major histocompatibility class II molecule, am P 2 and a, integrins, respectively. The CAR receptor is known to be expressed on melanoma cell lines (Hemmi S., et al, 1998). Heparan sulfate is recognised by Herpes simplex types 1 and 2 and human herpes virus 7, Adeno associated virus type 2. The receptor for human Herpesvirus 7 is CD4 while Epstein 20 Barr virus recognises complement receptor Cr2 (CD2 1). Poliovirus type 1 and 2 recognise poliovirus receptor (Pvr) for cell adhesion while reovirus recognises sialic acid. Influenza A and B virus recognise the sialic acid N-acetyl neuraminic acid for cell adhesion. In contrast, influenza type C virus recognises the sialic acid 9-0-acetyl WO 01/37866 PCT/AUOO/01461 -4 neuraminic acid. Vaccina virus recognises both epidermal growth factor receptor and heparan sulfate. Coxsackievirus A13, A15, A18 and A21 recognise ICAM-1 and the complement regulatory protein DAF (CD55) (see eg. Shafren D.R., et al 1997). DAF is also recognised by Enterovirus 70. See for instance Flint SJ, et al (2000) Principles of 5 Virology:molecular biology, pathogenesis and control. ASM Press, Washington. Metastatic tumour spread is a pathological process associated with a series of adhesion/de-adhesion events coupled with regulated tissue degradation. It is known that adhesion to and migration through the extracellular matrix is essential for tumour invasion. The largest family of extracellular adhesion molecules is the integrin family 10 (Marshall J.F. and Hart I.R., 1996) and members of the cvp group of integrins have been shown to be expressed on a variety of cell types. For instance ap I is expressed on neuroblastoma, melanoma and osteosarcoma cells, acp 3 is expressed on melanoma, glioblastoma and renal carcinoma cells, and cv5 is expressed on melanoma cells as is a48 (Marshall J.F. and Hart I.R., 1996). 15 Despite progress being made in the treatment of malignancies, the treatment of cancer including melanoma presents a major challenge for research and there remains the need for alternatives to existing therapy approaches. Summary Of The Invention The present invention stems from the surprising finding of significant killing of 20 abnormal cells can be achieved with the use of a virus and the recognition/interaction of cell expressed markers utilised by the virus for infectivity of the cells. In one aspect there is provided a method of treating abnormal cells in a mammal comprising administering to the mammal an effective amount of a virus capable of WO 01/37866 PCT/AUOO/01461 -5 infecting the abnormal cells whereby death of the cells is caused and which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells. The term "abnormal cells" for the purpose of the present invention is to be taken in 5 a broadest sense to include malignant cells, the cells of any abnormal growth and any cells having abnormal upregulated expression of at least one of the cell adhesion molecule and the complement regulatory protein relative to corresponding normal cells of the same cell type expressing their normal phenotype, whether the cells are cancer cells or not and whether the cells proliferate at an abnormal rate or not. Accordingly, the 10 term encompasses pre-neoplastic and neoplastic cells, and non-cancer cells that may or may not ultimately develop into cancer cells. An abnormal growth may for instance be a benign or malignant tumour. Typically, the abnormal cells will be malignant cells and usually melanoma cells. Generally, the expression of at least one of the cell adhesion molecule and the 15 complement regulatory protein will be upregulated compared to surrounding tissue in which the abnormal cells are found. Hence, the virus will typically preferentially infect the abnormal cells due to the greater likelihood of contacting at least one of the cell adhesion molecule and complement regulatory protein on those cells. As such the virus may be used to 20 effectively target the abnormal cells. In another aspect of the invention there is provided a method of treating melanoma in a mammal comprising administering to the mammal an effective amount of a virus capable of infecting melanoma cells whereby death of the cells is caused and wherein the WO 01/37866 PCT/AUOO/01461 -6 virus recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells. The virus may also be used to screen cells to ascertain for instance whether the virus may be suitable for treating the patient from which the cells were obtained or 5 whether a different treatment protocol not involving the virus may be more beneficial to the mammal. Conversely, different viruses may be screened using samples of cells taken from the patient in order to select the most appropriate virus for treating the mammal. Accordingly, in another aspect of the invention there is provided a method of screening abnormal cells for determining whether the cells are susceptible to viral 10 induced cell death, comprising the steps of: (a) providing the abnormal cells; (b) adding to the cells an effective amount of a virus which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells; 15 (c) incubating the abnormal cells in the presence of the virus for a period of time; and (d) determining whether the virus has infected and caused death of at least some of the abnormal cells. In a further aspect of the present invention there is provided a method of screening 20 melanoma cells for determining whether the cells are susceptible to viral induced cell death, comprising the steps of: (a) providing the melanoma cells; (b) adding to the melanoma cells an effective amount of a virus which WO 01/37866 PCT/AUOO/01461 -7 recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells; (c) incubating the melanoma cells in the presence of the virus for a period of time; and 5 (d) determining whether the virus has infected and caused death of at least some of the melanoma cells. A virus may be selected for use in a method of the invention by testing whether a given virus is capable of infecting and causing the death of abnormal cells expressing at least one of the cell adhesion molecule and the complement regulatory protein. In 10 particular, the testing may involve screening a number of different viruses by incubating each virus with a sample of the abnormal cells respectively, and determining whether the cells are killed as a result of infection. Accordingly, in another aspect of the present invention there is provided a method of testing whether a virus is capable of infecting abnormal cells whereby death of the 15 cells is caused and which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells. In a further aspect of the present invention, there is provided a method of testing whether a virus is capable of infecting melanoma cells whereby death of the cells is 20 caused and which recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells. In still another aspect of the invention there is provided a method of screening a virus for ability to infect and cause death of abnormal cells, comprising the steps of: WO 01/37866 PCT/AUOO/01461 -8 (a) selecting a virus which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells; (b) incubating the selected said virus with a sample of the abnormal cells for a 5 period of time; and (c) determining whether the selected said virus causes death of at least some of the abnormal cells. In another aspect of the present invention there is provided a method of screening a virus for ability to infect and cause death of melanoma cells, comprising the steps of: 10 (a) selecting a virus which recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells; (b) incubating the selected said virus with a sample of the melanoma cells for a period of time; and (c) determining whether the selected said virus causes death of at least some of 15 the melanoma cells. The method may also comprise the step of comparing the ability of the selected virus to infect and cause the death of the cells with that of another virus subjected to steps (b) and (c) utilising another sample of the cells. Death of the cells following infection with the virus may result from either lysis of 20 the cells due to intracellular replication of the virus or due to the infection triggering apoptosis most likely as a result of the activation of cellular caspases. Once lysed, the cytosolic contents of infected cells spills from the ruptured plasma membranes, and antigens capable of eliciting an immune response to the abnormal cells WO 01/37866 PCT/AUOO/01461 -9 may be released. Hence, treatment of abnormal cells in a mammal in accordance with a method of the invention may provide a boost to the immunity of the mammal against the abnormal cells. Accordingly, in another aspect of the invention there is provided a method of 5 inducing an immune response in a mammal comprising infecting abnormal cells in the mammal with a virus whereby death and lysis of the cells is caused with release of antigens therefrom for generation of said immune response, wherein the virus recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells. 10 In yet another aspect of the present invention there is provided a method of inducing an immune response in a mammal against melanoma cells, comprising infecting the melanoma cells in the mammal with a virus whereby death and lysis of the cells is caused with release of antigens therefrom for generation of said immune response, wherein the virus recognises at least one of a cell adhesion molecule and a 15 complement regulatory protein for infectivity of the melanoma cells. Generally, the virus will be provided in the form of a pharmaceutical composition for use in a method of the invention. As such, in a yet further aspect of the invention there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a virus capable of infecting abnormal cells whereby 20 death of the cells is caused and which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells.
WO 01/37866 PCT/AUOO/01461 - 10 In still another aspect of the present invention there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a virus capable of infecting melanoma cells whereby death of the cells is caused and which recognises at least one of a cell adhesion molecule and a complement regulatory protein 5 for infectivity of the melanoma cells. In another aspect is provided the use of the pharmaceutical composition in a method of the invention. In a further aspect of the invention there is provided the use of a virus in the manufacture of a medicament for treating malignant cells, wherein the virus is capable of 10 infecting the abnormal cells whereby death of the cells is caused and which recognises a cell adhesion molecule of the immunogolbulin (Ig) superfamily for infectivity of said abnormal cells. In another aspect of the present invention there is provided the use of a virus in the manufacture of a medicament for treating melanoma wherein the virus is capable of 15 infecting melanoma cells whereby death of the cells is caused and which recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells. In addition, there is provided delivery means for being held against the skin of a mammal for facilitating delivery of the virus to the mammal, and which is impregnated 20 with a pharmaceutical composition of the invention for contact with the skin, when the delivery means is held against said skin of the mammal in use. Generally, the delivery means will be adapted to enable it to hold in position over the skin at the desired site of treatment.
WO 01/37866 PCT/AUOO/01461 - 11 Preferably, the virus will be capable of binding to or otherwise associating with both the cell adhesion molecule and the complement regulatory protein. The complement regulatory protein will usually form a complex with the cell adhesion molecule or have a close spatial association with the cell adhesion molecule, and 5 enhance the ability of the virus to infect the abnormal cells. Preferably, the complement regulatory protein will be decay-accelerating factor (DAF). Preferably, the cell adhesion molecule is a member of the immunoglobulin (Ig) superfamily which includes V-CAM- 1 and the intercellular adhesion molecules ICAM 1, ICAM-2 and ICAM-3. Preferably, the cell adhsion molecule is ICAM-1. 10 Normally, the virus will be an animal RNA virus and typically, a non-enveloped RNA virus with an icosohedral capsid and a single RNA strand genome. Preferably, the virus will be a member of the Picornaviridae family. Members of the immunoglobulin (Ig) superfamily have a plurality of extracellular domains and the virus will desirably interact with the outermost domain closest to the N-terminus of the 15 immunoglobulin (Ig) superfamily molecule. Preferably, the virus will be from the genus Enterovirus and most preferably, the virus will be a Coxsackievirus. Coxsackievirus is a human enterovirus and most enteroviral infections, even with the more virulent members of the group, cause few or no clinical symptoms. CAV21 infection for instance is associated with development of common colds and infantile diarrhoea. 20 Hence, in another aspect of the present invention there is provided a method of treating abnormal cells in a mammal comprising administering to the mammal an effective amount of a Coxsackievirus.
WO 01/37866 PCT/AUOO/01461 - 12 In a still further aspect of the present invention there is provided a method of treating melanoma in a mammal comprising administering to the mammal an effective amount of a Coxsackievirus. Typically, the Coxsackievirus will be a Coxsackie A-group virus, and will 5 normally be selected from the group consisting of Coxsackieviruses serotypes 1 to 24 (CAV1-24), and most preferably from CAV13, CAV15, CAV18 and CAV21. While the virus will usually be a common animal virus the invention is not limited thereto and a recombinant virus engineered to be capable of infecting and causing the death of the abnormal cells, or a virus that has otherwise been modified to enhance its 10 ability to infect the cells and cause the death of the cells post infection, may be utilised. For instance, the virus may be modified to recognise additional cell adhesion molecules such as acp 3 , avp5 or ap 6 . Moreover, the same virus may be administered to the mammal during different treatment courses. Preferably, however, different viruses are used for different treatment 15 courses to avoid or lessen the potential effect of any immune response to the previous virus administered. The virus may for instance be administered topically, intratumourally or systemically to the patient. The mammal may be any mammal suffering from a malignancy and in need of treatment. Preferably, the mammal will be a human being. 20 A method of the invention may be used as an adjunct to conventional cancer treatment or as a treatment in the absence of other therapeutic treatments. In particular, a method of the invention may be utilised where conventional treatment is not suitable or practical, or in the instance where excision of abnormal cells may leave scaring or WO 01/37866 PCT/AUOO/01461 - 13 disfigurement which is unacceptable to the patient, particularly the patient's face such as from their nose or lip. Alternatively, the virus may be administered to the patient prior to and/or immediately after excision of abnormal cells. Accordingly, the instant methods provide an alternative therapeutic treatment 5 which may be used both following diagnosis of early stage and latter stage malignancy, and which further finds application for killing cells prior to and remaining after surgery. Using protocols as described herein the skilled addressee will be able to readily select a suitable virus for use in the methods of the invention, and determine which abnormal cells are susceptible to infection leading to the death of the cells. The 10 abnormal cells may for instance be prostate cancer cells, breast cancer cells, stomach cancer cells, gastric carcinoma cells, colon cancer cells, colorectal cancer cells, glioma cancer cells, skin cancer cells or other malignant cells. A method of the invention is particularly suitable for treating a malignancy of the skin or a malignancy that has spread from the skin such as melanoma. 15 Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to". The invention will now hereinafter be further described with reference to a number 20 of non-limiting preferred embodiments. Brief Description Of The Accompanying Drawings Figure 1 shows immunoperoxidase staining of surface ICAM- 1 expression on melanoma cells. ICAM-1 expression (white arrows) is indicated by dark cell staining; WO 01/37866 PCT/AUOO/01461 - 14 Figure 2 shows relative levels of ICAM-1 and DAF expression by the melanoma cell lines Sk-Mel-28 and ME4405; Figure 3 indicates lytic infection of two human melanoma cells lines by Coxsackievirus A21 at different time intervals post infection; 5 Figure 4 indicates lytic infection of human melanoma cells from a primary melanoma induced in a nude mouse with various doses of Coxsackievirus A2 1; Figure 5 indicates lytic infection of preparations of suspension and adherent primary malignant cells from a chest wall melanoma by Coxsackievirus A21 at 20 hours post infection; 10 Figure 6 (A) indicates lytic infection of six human melanoma cell lines by Coxsackievirus A21 at twenty-three hours post infection; (B) indicates results of flow cytometric analysis of DAF (dark line) and ICAM-1 (lighter line) on the surface of human melanoma cells; Figure 7 indicates lytic infection of different tumour cell lines by representative 15 human enteroviruses; Figure 8 indicates lytic infection of a human melanoma biopsy from lymph node by human enteroviruses Coxsackievirus A21 and B3; Figure 9 indicates lytic infection of prostate cancer cells by selected Coxsackievirus; 20 Figure 10 shows the capacity of CAV21 and CAV 15 to specifically lytically destroy melanoma cells without infecting non-melanoma cells; Figure 11 indicates subcutaneous administration of CAV21 infected cells to NOD SCID mice inhibits human melanoma tumour formation; WO 01/37866 PCT/AUOO/01461 - 15 Figure 12 is a graph showing results of intratumoural treatment of preformed Sk Mel-28 melanoma with CAV21; Figure 13 is a graph showing results of intratumoural treatment of preformed Sk Mel-28 melanoma with CAV 15; 5 Figure 14 shows Sk-Mel-28 tumours 35 days post inoculation with PBS (left tumour) and CAV 15 (right tumour); and Figure 15 is a graph showing the effect of intratumoural treatment of preformed ME4405 melanoma with CAV2 1. Detailed Description of Preferred Embodiments of the Invention 10 To determine whether a virus is capable of infecting and causing death of cells of a tumour, a biopsy may be taken from the tumour and a preparation of cells prepared using conventional techniques prior to: (i) confirming virus receptor cell surface expression and (ii) challenging the cells with the virus and monitoring the cells for infection and cell death over a predetermined incubation period, typically about 2 days although this may 15 vary depending on the virus used. A number of viruses may be screened in this way simultaneously utilising different aliquot's of the prepared malignant cells, the virus showing the greater degree of infectivity and cell death may then be selected for administration to the subject from whom the biopsy was taken. Similarly, different malignant cell preparations from biopsies taken from different sources may be employed 20 in an assay using a specific virus. The biopsies may be taken from different sites of a single individual or from a number of individuals. A virus used in a method as described herein will desirably cause few or only minor clinical symptoms in the recipient. Such viruses are readily obtainable from WO 01/37866 PCT/AUOO/01461 - 16 commercial sources well known to the skilled addressee and can be screened for their effectiveness in the instant methods in the manner described above. Desirably, the virus will normally be selected from Coxsackie A-group viruses. CAV21 is preferred and in particular CAV21 (Kuykendall) (Sickles G.M., Proc. Soc. Exp. Biol. Med. 102:742; 5 Shafren D. et al J. Virol 1997, 71:4736; Hughes et al, J. Gen Virol. 1989, 70:2943; Schmidt, N.J., et al, Proc. Soc. Exp. Biol. Med., 1961, 107:63. CAV21 (Kuykendall) is available from the American Type Culture Collection (ATCC) 10801 University Boulevard, Manassas, Virginia 20110-2209, United States of America under Accession No. VR-850. 10 For the purpose of simply screening a given virus to ascertain whether it is capable of infecting and causing the death of malignant cells, malignant cell lines may be used for this purpose rather than primary malignant cells isolated from a biopsy. Virus that recognises at least one of ICAM-1 and the complement regulatory protein DAF will typically be used. Besides being expressed on melanoma cells 15 (Cheung N.K. et al 1998), DAF has also been shown to have upregulated expression on colonic adenocarcinoma cells in situ and on the human colonic adenocarcinoma cell line HT29. The expression of DAF has been postulated to promote resistance of the cells to complement mediated damage and so represents a possible mechanism of tumour escape (Bjerge L., et al; 1996). 20 Upregulated expression of ICAM- 1 has been reported in a variety of malignant cell types including gastric carcinoma and adenoma cells (Nasu R., 1996; and Koyama S., 1992), prostrate cancer cells (Rokhlin O.W., and Cohen M.B., 1995), and human breast cancer cells (Sgagius M.K., 1996). Studies have also shown that V-CAM1 is expressed WO 01/37866 PCT/AUOO/01461 - 17 with ICAM-1 on beast cancer cells (Regidor P.A., et al; 1998). In addition, ICAM-1 is known to be expressed on medullary carcinoma cells (Bacuss S.S. et al; 1994), myeloma cells (Maloney D.G. et al; 1999) and thyroid carcinoma cells. ICAM-1 positive staining has also been reported in primary tumours such as papillary adenocarcinoma, and 5 metastatic tumours from brain, liver and the adrenal gland (Fernandez-Real J.M; 1996). Tumours occurring on the skin such as melanoma are particularly suitable candidates for treatment with the virus. In instances where melanoma has spread to lymph nodes, the lungs or other organs, the virus may be administered to those sites and/or the surrounding tissue as described above during a surgical procedure to expose 10 such sites for treatment. The selected virus will preferably be injected directly into a number of sites on a malignant tumour in order to maximise the area for potential infection of the tumour by the virus. Normally, tissue surrounding the tumour will be injected or otherwise treated with the virus given the possibility of malignant cells being present in the tissue. If the 15 tumour is not detected until it is relativity advanced, surrounding tissue may be injected with the virus following surgical excision of the tumour itself. Rather than being injected directly into a malignant tumour, the virus may be administered systemically by intravenous injection into the blood stream of the recipient at a location adjacent to the tumour site for delivery to the tumour. Similarly, the virus 20 may be administered subcutaneously, intraperitoneally or for instance, intramuscularly if deemed appropriate. Generally, however, direct injection into the tumour is preferred given the possibility of the existence of antibodies specific for the virus and thereby the potential decreased efficacy of alternate such modes of virus delivery.
WO 01/37866 PCT/AUOO/01461 - 18 The virus may also be applied topically to tumours either alone or in combination with direct injection of the virus into the tumour. In this instance, the virus may be applied by way of delivery means for being pressed against the malignant site on the skin to be treated and which is impregnated with a suitable pharmaceutically acceptable 5 carrier for maintaining the integrity of the virus to allow for infection of the malignant cells by the virus. The delivery means may be in the form of for instance, a patch, a pad, a wad, bandaging or the like suitable for localising the virus in the area to be treated. Typically, the delivery means will be a patch provided with an adhesive around an underside perimeter thereof for sticking the patch on the skin and thereby holding the 10 patch in the desired position and the inoculant in contact with the patients skin. Generally, one or more small incisions will be made into the malignancy and/or surrounding tissue to provide a site of entry for the virus into same. The carrier medium used for inoculating the recipient with the virus may be a fluid such as physiological saline, or any other conventionally known medium deemed 15 appropriate such as commercially available gels suitable for pharmaceutical use and for administering the virus to the site of treatment. The inoculant will generally contain from about 1 x 102 to about 1 x 10 plaque forming units per ml of the inoculant. Preferably, the inoculant will contain greater than about 1 x 10 5 plaque forming units per ml of inoculant. The amount of inoculant 20 administered to the patient may be readily determined by the attending physician or surgeon in accordance with accepted medical practice taking into account the general condition of the patient, the stage and location of the malignancy together with the overall size and distribution of the area to be treated with the virus. Typically, the WO 01/37866 PCT/AUOO/01461 - 19 patient will be treated with an initial dose of the virus and subsequently monitored for a suitable period of time before a decision is made to administer further virus to the patient pending factors such as the response of the patient to the initial administration of the virus and the degree of viral infection and malignant cell death resulting from the initial 5 treatment. Desirably, an individual will be treated with the virus over a period of time at predetermined intervals. The intervals may be daily or range from 24 hours up to 72 hours or more as determined appropriate in each circumstance. The same or a different virus may be administered each time to avoid or minimise the effect of any immune 10 response to a previously administered virus, and a course of treatment may extend for one to two weeks or more as may be determined by the attending physician.. Most preferably, virus to which the mammal has not previously been exposed or to which the mammal generates a relatively minor immune response as may be determined by standard techniques will be administered. 15 While readily available known viruses may be suitably employed in a method of the invention, a virus modified or engineered using conventional techniques may also be utilised. For instance, a virus may be modified to employ additional cell adhesion molecules as cell receptors. For example, Coxsackievirus A21 may be modified using site-directed mutagenesis so that the peptide motif "RGD" is expressed on the viral 20 caspid surface as is the case with Coxsackievirus A9 (CAV-9). The RGD motif is recognised by all the av integrin heterodimers and this capsid modification may for instance allow the virus to bind the integrin avp 3 , a cell adhesion molecule which has been shown to be up-regulated in combination with ICAM- 1 on the surface of malignant WO 01/37866 PCT/AUOO/01461 - 20 melanoma lesions (Natali P.G.; 1997) leading to enhanced uptake of the virus via interaction with the integrin molecule or subsequent interaction with ICAM-1. Alternatively, the virus may be modified to recognise a selectin such as E-selectin. The invention will now be described with reference to a number of examples 5 described below. Example 1 1.1. CellLines Continuous cultures of Rhabdomyosarcoma expressing ICAM- 1 cells (RD-ICAM 1), HeLa-B cells, and human lung fibroblast cells (MRC5) were maintained in 10 Dulbecco's Modified Eagle's Medium (DMEM) and 10% fetal calf serum (FCS). Two melanoma cell lines Sk-Mel-28 and ME4405 were obtained from Dr. Ralph (Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia) and Dr. Peter Hersey, Cancer Research Department, David Maddison Building Level 4, Royal Newcastle Hospital, Newcastle, New South Wales, Australia, respectively. The cell line 15 Sk-Mel-28 is a metastatic melanoma cell line found to be resistant to chemotherapeutic drugs (56). The melanoma cell culture ME4405 was established from specimens of primary melanoma lesions (69). The two melanoma cell lines were maintained in DMEM containing 10% FCS. Rhabdomyosarcoma cells (RD) a heteroploid human embryonal cell line, and HeLa-B cells an aneuploid cell clone derived from human 20 squamous epithelial cells, were obtained from the Entero-respiratory Laboratory, Fairfield Hospital, Melbourne, Victoria, Australia. RD cells stably transfected with cDNA encoding the immunoglobulin superfamily molecule ICAM-1 providing the RD- WO 01/37866 PCT/AUOO/01461 -21 ICAM- 1 cell line have been described elsewhere (Shafren DR, et al; 1997). MRC5 cells, derived from human lung fibroblasts were obtained from Bio-Whittaker, USA. 1.2. Viruses Strains of CAV21 (Kuykendall strain), CAV15 (G-9) and CVB3 (Nancy) were 5 obtained from Margery Kennett, Entero-respiratory Laboratory, Fairfield Hospital, Melbourne, Victoria, Australia. 1.3. Virus Propagation RD-ICAM-1 cultures (80-95% confluent) were infected with 10 4
TCID
5 0 (50% tissue culture infectious dose) of Coxsackievirus A strains according to standard 10 procedures. Infected cells were incubated at 37'C until complete cytopathic effect was observed (within 2 days). Cells were then frozen at -80*C and thawed to release the remaining intracellular virus particles. The virus-containing medium was clarified of cellular debris by centrifugation for 5 min at 1000 x g and stored as 500 pl aliquots at -80'C. CVB3 was propagated in HeLa-B cells in the same manner as described above. 15 1.4 Monoclonal Antibodies (MAbs) MAb IH4 which recognises the third SCR of DAF (24) was a gift from Dr. B. Loveland, Austin Research Institute, Melbourne, Victoria, Australia. MAb WEHI-CAM recognises the first domain of ICAM- 1 (Berendt AR, et al; 1992) and was provided by Dr. A. Boyd, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia. 20 1.5. Flow Cytometric Analysis Cells (1x10 6 ) in 100 pl aliquots were incubated with Mab IH4 or Mab WEHI CAM diluted in DMEM containing 1% FCS on ice for 30 min. The cells were then washed with 5.0 ml of PBS, pelleted at 1,000 x g for 5 min and resuspended in 100 pl of WO 01/37866 PCT/AUOO/01461 - 22 fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin G (Silenus, Melbourne, Australia) diluted in PBS. Following incubation on ice for 30 min the cells were washed and pelleted, and resuspended in PBS for analysis with a FACStar analyser (Becton Dickinson, Sydney, Australia). 5 1.6. Colourimetric Infectivity Assay The stock virus solutions of CAV21 and CAV15 were serially diluted 10-fold in DMEM containing 1% foetal calf serum (FCS). RD-ICAM-1 cell monolayers in 96-well plates were inoculated with 100 l of serial dilutions of the viruses for 48h at 37*C. To quantitate cell survival, monolayers were incubated with 100 l of a crystal violet 10 methanol solution (5% w/v crystal violet, 10% v/v methanol, 10% v/v formaldehyde solution in PBS) and washed with distilled water. The plates were read on a multiscan enzyme-linked immunosorbent assay plate reader at a wavelength of 540 nm. Fifty percent endpoint titres were calculated (Reed LJ and Muench HA; 1938) and expressed as 50% tissue culture infectious dose (TCID 50 ) per millilitre. A well was scored positive 15 if absorbance was less than three standard deviations of the no-virus control. The
TCID
5 0 for CAV21 was determined to be 2.7 x 104 units per ml while for CAV 15, the
TCID
50 was determined to be 1.6 x 10 4 units per ml. 1.7. Surface Expression of ICAM-1 and DAF The relative levels of ICAM- 1 and DAF expression on the surface of the 20 melanoma cell lines SK-Mel-28 and ME4405 was determined by flow cytometric analysis. The results are shown in Fig 2. As can be seen, flow cytometric analysis revealed comparable high level ICAM- 1 and DAF expression on the surface of the two melanoma cell lines. A further 6 WO 01/37866 PCT/AUOO/01461 -23 melanoma cell lines derived from metastatic melanomas also expressed high levels of ICAM- I and DAF (data not shown). The finding of high level ICAM- 1 expression on all the metastatic melanoma cells tested supports several reports in the literature noting increased levels of ICAM- 1 expression in vivo correlates with increased metastatic 5 ability (Johnson JP, et al:1988; Kageshita T, et al:1993; Miller BE and Welch DR:1990; Natalie PG, et al:1997). Example 2 2.1. Infection of Melanoma Cell Lines by CA V21 10 Monolayers of two culture-adapted melanoma cell lines Miller and MM200 were infected with CAV21 prepared in Example 1 at a multiplicity of infection of 1.0 for 1 hour prior to removal of the inoculum and the cells incubated in culture medium (DMEM containing 1% foetal calf serum and penicillin streptomycin) for 24 hours at 37'C. The results shown in Fig. 3 indicate that CAV21 was able to induce significant 15 changes in the cellular cytopathology of both cell lines as early as five hours post infection (PI) and by nine hours PI almost complete killing of all the melanoma cells. Example 3 3.1. Infection of Melanoma Cells from Primary Melanoma by CA V21 20 Cells from a primary melanoma removed from a nude mouse that had been previously subcutaneously inoculated with human melanoma cells from cell line ME 4405 using conventional methods, were highly susceptible to CAV21 infection and WO 01/37866 PCT/AUOO/01461 - 24 killing, even at a challenge rate of 0.005 CAV21 particles per melanoma cell as shown in Fig. 4. Example 4 5 4.1. Infection of Melanoma Cells Isolated From Tissue Biopsy by CAV21 Melanoma cells were isolated from fresh biopsy of a primary chest wall melanoma by the "spilling" technique and by digestion in collagen-trypsin and DNAase. Briefly, cells were released from the melanoma biopsy by macerating the biopsy with the plunger of a 1 Oml syringe. The resulting melanoma cell suspension was purified on a Ficol 10 Hypaque (Amersham Pharmacia, Uppsala, Sweden) gradient. Contaminating fibroblasts and leucocytes were removed by mixing with Dynal beads coated with monoclonal antibodies (Mab's) to human fibroblasts (Cat#; MAS516X, SeraLab) and to the leucocyte common antigen (CD45, Cat# 17-0804-3, Amrad Biotech, Victoria, Australia). Subsequently, 1 x 106 cells were placed into wells of a 24-well tissue culture plate 15 and inoculated with approximately l x 105 plaque forming units of CAV21 prepared in Example 1. Following incubation at 37*C for 20 hours, cells were assessed for cell death by staining with propridium iodine and microscopic analysis. Fig. 5 shows that both adherent and suspension primary melanoma cells were efficiently killed as a result of CAV21 infection during the 20 hour incubation period. 20 WO 01/37866 PCT/AUOO/01461 - 25 Example 5 5.1 Expression of ICAM-1 and DAF on Melanoma Cells Susceptible to CA V21 Infection To confirm melanoma cells are highly susceptible to infection and resultant killing 5 by CAV2 1, six additional human melanoma cell lines derived from primary human melanomas were infected with CAV21 prepared in Example 1. Fig. 6(A) indicates that all melanoma cell lines except one (ME 105) were killed as a result of CAV21 infection during a 23 hour incubation period. To confirm high level expression of ICAM- 1 and DAF on the surface of malignant 10 melanoma cells, cells from each cell line were treated with the Mab IH4 and Mab WEHI-CAM. The binding of the anti-DAF and anti-ICAM-1 Mab was detected by flow cytometric analysis as described above. The fluorescence histograms shown in Fig. 6(B) confirm high level expression of DAF and ICAM- 1 on the surface of all melanoma cell lines examined except the ME 105 cell line. The lack of DAF and ICAM-1 expression 15 rendered this cell line refractile to CAV21 infection. Example 6 6.1 Selective Infection of Melanoma Cells Expressing ICAM-1 To highlight the selective nature of CAV21 infection of ICAM-1 expressing 20 human melanoma cells, monolayers of melanoma cell line MM 200 were inoculated with approximately 1 x 105 plaque forming units of CAV21, Coxsackievirus B3 (CVB3), Echovirus type 7 (E7) or Coxsackievirus BI (CVB1) in wells of a 24-well tissue culture plate for one hour at 37*C, respectively. The viral inoculate was WO 01/37866 PCT/AUOO/01461 - 26 subsequently removed and the cell monolayers then washed with phosphate buffered saline (PBS), and 1.0 ml of DMEM containing 1.0% foetal calf serum was addded to each well and the cells incubated at 37'C for 48 hours. To quantitate cell survival, monolayers were incubated with a crystal violet/methanol solution, washed with distilled 5 water and microscopically examined at 100 X. Fig. 7 shows that following the 48 hour incubation period only CAV21 infected the MM 200 melanoma cells while the reverse occurred in the rhabdomyosarcoma cells (RD) where CVB 1, CVB3 and E7 infection and killing is evident. RD cells express DAF but no ICAM- 1. However, when ICAM- 1 is expressed on the surface of RD cells 10 they are highly susceptible to CAV21 induced infection and killing. Example 7 7.1 Infection of Melanoma Biopsy With CA V21 Sections of solid human melanoma lymph node biopsies were placed in wells of a 15 24-well tissue culture plate and mock infected or challenged with approximately l x 105 plaque forming units of CAV21 or CVB3. The results shown in Fig. 8 indicate that CAV21 infection resulted in severe tissue destruction around the perimeter of the melanoma biopsy treated with that virus while no detectable viral membrane destruction was observed in the mock and CVB3 infected 20 biopsies. Example 8 8.1. Lytic Infection of Human Melanoma Cells by CAV21 and CAVJS WO 01/37866 PCT/AUOO/01461 -27 To assay the oncolytic potential of CAV15 and CAV21 on human melanoma cell lines, Sk-Mel-28 and ME4405 cells were seeded into flat-bottom 96-well microtiter plates (Becton Dickinson) at 3 x 104 cells per well. Following incubation for 24 h at 37 0 C, culture medium was removed and replaced with fresh medium containing the 5 appropriate viral serial dilution in a final volume of 100 [d. Stock viral preparations 7 were serially diluted 10 ' through to 10 . Following viral inoculation, the plates were incubated at 37'C for 48 h and cell survival was detected by crystal violet staining as described above. All three cell lines RD-ICAM-1, Sk-Mel-28 and ME4405 were found to be 10 permissive to lytic infection by both CAV21 and CAV15. Following an incubation period of 48 h, the no virus control showed no signs of viral induced CPE while extensive cell lysis was observed across all cell cultures at a dilution of 10- and 10-2. At higher viral dilutions Sk-Mel-28 cells were shown to be more permissive to viral lysis compared to ME4405 and RD-ICAM-1 cell lines. 15 The overall oncolytic potential of CAV21 and CAV 15 was higher in the melanoma cell lines, compared to the control RD-ICAM-1 cells. While all cell types express similar levels of ICAM- 1, DAF expression in RD-ICAM- 1 cells is significantly lower than on melanoma cells (see Fig. 2) accounting for lower viral attachment via DAF to RD-ICAM-1 cells. DAF has previously been shown to be a low affinity sequestration 20 molecule for many Coxsackieviruses, assisting the capture of virus particles and hence infectivity of the cells(Lea SM, et al; 1998). The presence of higher levels of DAF expression on the melanoma cell lines compared to the RD-ICAM-1 cells increases the WO 01/37866 PCT/AUOO/01461 -28 probability of viral access to ICAM-l receptors, thus leading to an increased level of infection and cell lysis. 8.2. Lytic Infection of Human Prostate Cancer Cells by Coxsackievirus Cells from the human prostate cancer cell line CP3 (which expresses ICAM-1) 5 were seeded into a flat-bottom 96-well microtitre plate (Becton Dickenson) at 3 x 104 cells per well and treated with serial dilutions of CAV 13, CAV 15, CAV21 and the Coxsackievirus B-group virus CVB3 following incubation of the cells, as described in Example 8.1 above. PC3 cells are available from the American Type Culture Collection (ATCC) Manassas, Virginia, USA under Accession No. CRL-1435. 10 As shown in Fig. 9, the PC3 cells were highly permissive to lytic infection by CAV 15. Extensive lytic infection was also observed for both CAV 13 and CAV2 1. 8.3. Selective Replication of CA V21 and CA V15 in the Human Melanoma Cell Lines Sk-Mel-28 and ME4405 The selectivity of CAV21 and CAV 15 for the melanoma cell lines Sk-Mel-28 and 15 ME4405 was studied using an in vitro specificity assay. Sterile cell culture inserts were used to divide the wells of a standard six well plate tissue culture plate. Inside the cell culture insert, either Sk-Mel-28 cells or ME4405 cells were grown, with MRC5 or RD cells grown around the cell culture insert. Once the cells had adhered, the cell culture inserts were removed from each of the well 20 allowing the cell culture media to evenly cover the co-culture. When the perimeters of both cell populations had fused, the co-cultures were washed twice with PBS and then inoculated with 500 pl of either PBS or stock virus (105 TCID 50 ) for 1 h at 37 0 C. Following incubation at 37'C, fresh DMEM containing 1% FCS was added to each of WO 01/37866 PCT/AUOO/01461 - 29 the wells and the plates incubated for 48 h at 37*C in a 5% CO 2 atmosphere. Cell monolayers were monitored by light microscopy for signs of virus-induced CPE, prior to each well being stained with 3 ml of crystal violet solution for the detection of cell survival from viral induced lytic infection. The capacity of CAV21 and CAV15 viruses 5 to specifically lytically destroy melanoma cells without infecting non-melanoma surrounding cells is illustrated in Figure 10. As can be seen, the inner cultures of melanoma cells in each well treated with CAV21 or CAV 15 were totally destroyed by the viruses, but were unaffected by CVB3 virus which does not employ ICAM-1 as a receptor for cell entry. CVB3 which employs 10 the Coxsackie-and adenovirus receptor (CAR) for cell entry (10). MRC5 cells appeared to be refractory to lytic infection by both CAV21 and CAV15. These cells are derived from a human lung fibroblast culture and only express low levels of ICAM-1 (unpublished data). The present data shows that rapid and effective lytic infection of target cells facilitated high level ICAM-1 and DAF expression. RD cells, which do not 15 express ICAM-1, were not destroyed by either CAV21 or CAV15 infection. Furthermore, the results show little if any spread of CAV21 and CAV15 to receptor negative cells that are in direct contact with virally infected receptor-bearing cells. Example 9 20 The lytic infection of preformed melanoma tumours in vivo was evaluated by a series of animal challenge experiments using NOD-SCID mice. 9.1. Development of Melanoma Xenografts in NOD-SCID Mice WO 01/37866 PCT/AUOO/01461 - 30 All animal work was performed under guidelines approved by The University Of Newcastle Animal Care and Ethics Committee. NOD-SCID mice were housed in pathogen-free quarters in the animal handling facility located at the David Maddison Building, Level 5, Newcastle, NSW, Australia. 5 Sk-Mel-28 and ME4405 cells were grown in DMEM containing 10% FCS. The cells were harvested and washed twice with DMEM, and resuspended in sterile PBS. The cell concentration of the suspension was determined with a haemocytometer and cell viability was assessed by trypan blue staining. Only cell preparations with >95% viability were used for xenotransplantation. Prior to xenotransplantation, animals were 10 anaesthetised with intraperitoneal (i.p) injections of Rompun/Ketamine (50 mg/kg). For the monitoring of animals and measurement of tumour growth, animals were anaesthetised with 3% isofluorane. The tumour cells were xenografted into the flank of anaesthetised 4-6 week old female NOD-SCID mice. Xenograft tumour growth was observed daily and measured 15 with callipers at various intervals with all measurements recorded in millimetres over the course of 5 weeks. Estimates of tumour volumes were calculated using known methods (Davies CD, et al; 1997). 9.2. Subcutaneous Viral Delivery In a preliminary experiment employing fifteen NOD-SCID mice, the local 20 subcutaneous delivery of virus through ex vivo infected cells was assessed for inhibition of tumour growth. The mice in the control group (n=-5) were injected subcutaneously with Sk-Mel-28 cells (1x10 7 ) cells at individual sites in both the upper and lower flank. The CAV21 group (n=5) received an injection of 1x 107 Sk-Mel-28 cells in the upper WO 01/37866 PCT/AUOO/01461 -31 flank and a second injection of Sk-Mel-28 (1x10 7 ) cells that had been pre-incubated with 10 4
TCID
50 of CAV21 at room temperature for 1 hour ex vivo. The CAV 15 group (n=5), was treated the same as the CAV21 group except that the second injection in the lower flank contained Sk-Mel-28 (1x10 7 ) cells that had been incubated with 10 4
TCID
5 0 of 5 CAV15. Four weeks post-injection, a representative of the control group was sacrificed and shown to bear two individual tumour masses corresponding to the two injections sites of the Sk-Mel-28 (1x10 7 ) cells. In contrast a representative of the CAV21 group beared no detectable tumour formation in either the uninfected cell or virally infected cell sites of injection (Figure 11). Upon autopsy examination, all remaining members of 10 the control group were shown to possess two distinct melanoma xenograft tumour growths, while remaining members of the CAV21 group (17 weeks post injection) exhibited no detectable tumour growth in either site of injection. Mice in the CAV15 group exhibited no tumour formation at 4 weeks post- injection. 9.3. Intratumoural Viral Delivery 15 Twenty NOD-SCID mice were injected with Sk-Mel 28 cells (1 x 107) in the upper flank. When the tumour volume reached ~ 50-100 mm the animals were randomly divided into groups of five and housed in separate cages. Groups of mice were injected intratumourally with 100 ptl of active CAV21 or CAV15 containing 103 or 1042 TCID 50 doses, respectively. The remaining animals received 100 pl of PBS 20 injected directly into the xenografts. The different treatment groups were housed in individually vented cages maintained under negative pressure, ensuring that virus and other pathogens were contained within the individual cages.
WO 01/37866 PCT/AUOO/01461 - 32 A dose of 10 or 10- TCID 50 of either CAV21 or CAV 15 respectively, was sufficient to produce significant tumour reduction in animals bearing preformed Sk-Mel 28 tumours at 14 days post-injection. The trend of reduction of tumour burden continued for the next 14-21 days. No detectable tumours were observed at 30-35 days 5 post-injection (see Figures 12 and 13). The difference observed between the CAV21 treated group and the PBS treated control group was statistically significant (P=0.0023, t test). Animals bearing Sk-Mel-28 tumours and injected with CAV21 showed no clinical signs of CAV21 illness. The capacity of CAV 15 to drastically reduce melanoma tumour burden is shown in Figure 14. At 35 days post-injection, the melanoma xenograft treated 10 with PBS was approximately 2037 mm while the CAV15 treated tumour was approximately 2 mm 3 in volume (P=0053, t test). The CAV15 treated tumour shown comprises mostly residual connective tissue. 9.4. Intratumoral Delivery of CA V21 to ME4405 Xenograft The intratumoural delivery of CAV21 to a different melanoma (ME4405) 15 xenograft was undertaken to further confirm the anti-tumour therapy potential of this virus. Fifteen NOD-SCID mice were injected with ME4405 cells (5x10 6 ) subcutaneously in a single site on the flank. When tumour volumes had reached approximately 500 mm 3 , the animals were randomly divided into groups of five and housed in separate cages. Five animals were injected intratumourally with 100 il of active CAV21 containing 20 103.2 TCID 50 doses, while five mice received 100 ptl of PBS injected directly into the xenografts and the remaining five mice were left untreated. As shown in Fig. 15, intratumoural administration of CAV21 was able to markedly reduce tumour development of ME4405 cells within 25 days post-injection even though the initial pre- WO 01/37866 PCT/AUOO/01461 - 33 injection tumour volume was 5-fold greater than those utilised above. The ME4405 xenografts were observed to be more aggressive than the Sk-Mel-28 tumours as assessed by significantly faster growth rates of tumours in the control groups. The ME4405 cell line generated highly vascular aggressive tumours compared to 5 Sk-Mel-28 tumours which grew at a slower rate and were not as vascular as the ME4405 tumours. In contrast to mice bearing Sk-Mel-28 xenografts, when CAV21 was injected into animals with ME4405 tumours, some signs of illness were observed, the most notable being a transient weakness in both the fore and hind limbs. No positional 10 abnormalities were observed. 9.5. Discussion of Results This study demonstrates that CAV13, CAV15 and CAV21 have the capacity to lytically destroy malignant cell lines. Specifically, the in vitro analysis of CAV21 and CAV15 infection of melanoma 15 cells shows that these two viruses are able to selectively infect Sk-Mel-28 and ME4405 cell lines as a result of the expression of ICAM-1 and DAF while each of the Coxsackieviruses mentioned above were able to infect and cause the death of cells of the prostate cancer line PC3. Moreover, the intratumoural injection of CAV21 and CAV15 into xenografts of human melanoma cell lines grown in the flanks of NOD-SCID mice 20 show that CAV21 and CAV15 possess therapeutic applications against malignant melanoma. The direct injection of either of the two viruses into pre-formed melanoma tumours suppressed tumour growth and led to significant tumour regression and in some cases complete tumour destruction compared to control animals. Furthermore, the WO 01/37866 PCT/AUOO/01461 - 34 delivery of cells infected by virus ex vivo yielded total inhibition of tumour growth and demonstrates that ex vivo CAV21 infected melanoma cells are capable of delivering sufficient virus to inhibit local tumour growth. In addition, injection of infected cells subcutaneously in a distant region to the initial tumour challenge shows that the virus 5 can travel systemically. The pathogenesis of CAV21 and CAV15 infections are mainly asymptomatic or manifest by no more than minor malaise. The Coe strain of CAV21 has recently been approved for live administration by the Food and Drug Administration (FDA) of the United States of America for the clinical assessment of specific anti-viral agents against 10 CAV21 (90). The recent development of specific antiviral agents against CAV21 and CAV15 provides the added safety precaution of drug intervention to control viral infection. Although the present invention has been described hereinbefore with reference to a number of preferred embodiments, the skilled addressee will understand that numerous 15 modifications and variations are possible without departing from the scope of the invention.
WO 01/37866 PCT/AUOO/01461 - 35 REFERENCES CITED: 1. Kageshita T, Yoshii A, Kimura T, Kuriya N, Ono T, Tsujisaki M, Imai K and Ferrone S (1993). Clinical relevance of ICAM-1 expression in primary lesions and serum ofpatients with malignant melanoma. Cancer Res. Oct 15; 53(20):4927-32. 5 2. Kraus A, Masat L and Johnson JP (1997). Analysis of the expression of intercellular adhesion molecule-] and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognising denatured, non-glycosylated antigen. Melanoma Res. Aug 7; Supply 2:S75-81. 10 3. Morandini R, Boeynaems JM, Hedley SJ, MacNeil S and Ghanem G (1998). Modulation of ICAM-1 expression by alpha-MSH in human melanoma cells and melanoxytes. J Cell Physiol. Jun; 175(3):276-82. 4. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD and Springer TA (1989). A cell adhesion molecule, ICAM-1 is the major surface receptor for 15 rhinoviruses. Cell. 56:849-853. 5. Cheung NK, Walter El, Smith-Mensah WH, Ratnoff WD, Tykocinski ML and Medof ME (1998). Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. Apr; 81(4):1122-8. 6. Nemunaitis J (1999). Oncolytic viruses. Investigational New Drugs 17:375-3 86 20 7. Fenner F, McAuslan BR, Mims CA, Sambrook J and White DO. The Biology of Animal Viruses. Academic Press, New York, 1974 Second Ed.
WO 01/37866 PCT/AUOO/01461 - 36 8. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP and Fueyo J (1999). Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res. 252:1-12. 9. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B 5 and Whitley RJ (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93:11313-8. 10. Coffey MC, Strong JE, Forsyth PA and Lee PWK (1998). Reovirus therapy of lumours with activated Ras pathway. Science. 282:1332-1334. 10 11. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PWK (1998). The molecular basis of viral oncolysis: usurpation of the Ras signalling pathway by reovirus. 17(12):3351-3362 12. Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, Maclean A and Fraser NW (1995). Treatment of experimental intracranial murine melanoma 15 with a neuroattenuated herpes simplex virus 1 mutant. Virology 211:94-101. 13. Satyamoorthy K, Soballe PW, Soans F and Herlyn M (1997). Adenovirus infection enhances killing of melanoma cells by a mitotoxin. Cancer Research 57:1873 1876. 14. Hemmi S, Geertsen R, Mezzacasa A, Peter I and Dummer R (1998). The presence 20 of human Coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Human Gene Therapy 9:2363-2373.
WO 01/37866 PCT/AUOO/01461 - 37 15. Shafren DR, Dorahy DJ, Ingham RA, Bums GF and Barry RD (1997). Coxsackievirus A 21 binds to decay-accelerating factor but requires intercellular adhesion molecule Ifor cell entry. J Virol. Jun; 71(6):4736-43. 16. Flint SJ, Enquist LW, Krug RM, Racaniello VR and Skalka AM (2000). Principles 5 of'virology. molecular biology, pathogenesis, and control. ASM Press, Washington. 17. Marshall JF and Hart IR (1996). The role of av-integrins in tumour progression and metastasis. 18. Bjerge L, Jensen TS and Matre R (1996). Characterisation of the complement 10 regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother. 42:185-192. 19. Nasu R, Mizuno M, Kiso T, Shimo K, Uesu T, Nasu J, Tomoda J, Okada H and Tsuji T (1997). Immunohistochemical analysis of intercellular adhesion 15 molecule-] expression in human gastric adenoma and adenocarcinoma. Virchows Arch 430:279-283. 20. Koyama S, Ebihara T and Fukao K (1992). Expression of intercellular adhesion molecule ] (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J. Cancer Res. Clin. Oncol. 118:609-614. 20 21. Rokhlin OW and Cohen MB (1995). Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate. Apr; 26(4):205-12.
WO 01/37866 PCT/AUOO/01461 - 38 22. Sgagias MK, Nieroda C, Yannelli JR, Cowan KH and Danforth Jr. DN (1996). Upregulation of DF3, in association with ICAM-] and MHC class II by IFN gamma in short-term human mammary carcinoma cell cultures. Cancer Biother Radiopharm. 11:177-85. 5 23. Regidor PA, Callies R, Regidor M and Schindler AE (1998). Expression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera. Eur J Gynaecol Oncol. 19:377-83. 24. Bacuss SS, Zelnick CR, Chin DM, Yarden Y, Kaminsky DB, Bennington J, Wen D, Marcus JN and Page DL (1994). Medullary carcinoma is associated with 10 expression of intercellular adhesion molecule-]. Implication to its morphology and its clinical behaviour. Am J Pathol. Dec; 145(6):1337-1148. 25. Maloney DG, Donovan K and Hamblin TJ (1999). Antibody therapyfor treatment of multiple myeloma. Seminars in Hematology. 36 (1 Suppl 3):30-33. 26. Fernandez-Real JM, Villabona C, Fernandez-Castaner M, Sagarra E, Gomez-Saez 15 JM and Soler J (1996). Expression of ICAM-1 in distant metastatic thyroid carcinoma. J Endocrinol Invest. Mar; 19(3):183-185. 27. Natalie PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, Giannarelli D, Temponi M, Ferrone S (1997). Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-] expression in 20 cutaneous malignant melanoma lesions. Cancer Res. Apri 15; 57(8):1554-60. 28. Reed U and Muench HA (1938). A simple method of estimating fifty percent endpoints. Am J Hyg. 27:493-497.
WO 01/37866 PCT/AUOO/01461 - 39 29. Berendt AR, McDowall A, Craig AG, Bates PA, Sternberg MJE, Marsh K, Newbold CI and Hogg M (1992). The binding site on ICAM-1 for plasmodium falciparum-infected erythrocytes overlaps, but is distinct from the LFA-1 binding site. Cell. 68:71-81. 5 30. Johnson JP, Stade BG, Hupke U, HolzmannB, Schwable W and Reithmuller G (1988). The melanoma progression-associated antigen P3.58 is identical to the intercellular adhesion molecule ICAM-1. Immunology. 178:275-284. 31. Miller BE and Welch DR (1990). Intercellular adhesion molecule-1 (ICAM-1) expression by human melanoma cells; association with leukocyte aggregation and 10 metastatic potential. Clin. Exp. Metastasis. 8:80. 32. Lea SM, Powell RM, McKee T, Evans DJ, Brown D, Stuart DI and van der Merwe PA (1998). Determination of the affinity and kinetic constants for the interaction between the human virus echovirus 11 and its cellular receptor, CD55. J. Biol. Chem. 273:30443-60447. 15 33. Davies CDL, Muller H, Hagen I, Garseth M and Hjelstuen MH (1997). Comparison of extracellular matrix in human osteosarcomas and melanomas growing as xenografts, multicellular spheroids and monolayer cultures. Anticancer Research. 17:4317-4326. 20

Claims (129)

1. A method of treating abnormal cells in a mammal comprising administering to the mammal an effective amount of a virus capable of infecting the abnormal cells whereby 5 death of the cells is caused and which recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells.
2. A method according to claim 1 wherein the cell adhesion molecule is ICAM-1.
3. A method according to claim 1 or 2 wherein the virus recognises both the cell 10 adhesion molecule and the complement regulatory protein for infectivity of the abnormal cells.
4. A method according to claim 1 wherein the virus recognises the complement regulatory protein for infectivity of the abnormal cells.
5. A method according to claim 3 or 4 wherein the complement regulatory protein is 15 DAF.
6. A method according to any one of claims 1 to 3 -herein expression of the cell adhesion molecule is upregulated on the abnormal cells relative to normal said cells expressing their normal phenotype.
7. A method according to any one of claims 1 to 3 wherein expression of the cell 20 adhsion molecule is upregulated on the abnormal cells relative to cells of surrounding tissue in which the abnormal cells are found.
8. A method according to any one of claims 1 to 7 wherein the virus is an animal RNA virus. WO 01/37866 PCT/AUOO/01461 - 41
9. A method according to any one of claims 1 to 8 wherein the virus is an Enterovirus.
10. A method according to claim 9 wherein the virus is a Coxsackievirus.
11. A method according to claim 10 wherein the virus is selected from the group 5 consisting of CAV- 13, CAV- 15, CAV- 18 and CAV-2 1.
12. A method according to any one of claims I to 11 wherein the virus is a recombinant virus.
13. A method according to any one of claims 1 to 12 wherein the abnormal cells are cells of a malignancy selected from the group consisting of a malignancy of the skin, 10 prostate cancer, stomach cancer, breast cancer and colon cancer.
14. A method according to any one of claims 1 to 13 wherein the virus is administered intravenously, intratumorally, intraperitoneally, intramuscularly, or by topical application.
15. A method according to any one of claims 1 to 14 wherein the virus is administered 15 by injection.
16. A method according to any one of claims 1 to 15 wherein the virus is administered to the patient in a dosage greater than about lx102 plaque forming units per ml of innoculant.
17. A method according to claim 16 wherein the virus is administered to the patient in 20 a dosage of between about 1x102 to 1xl10 plaque forming units per ml of the innoculant.
18. A method of treating melanoma in a patient comprising administering to the patient an effective amount of a virus capable of infecting melanoma cells whereby death WO 01/37866 PCT/AUOO/01461 - 42 of the cells is caused and wherein the virus recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells.
19. A method according to claim 18 wherein the cell adhesion molecule is a member of the immunoglobulin (Ig) superfamily. 5
20. A method according to claim 18 or 19 wherein the cell adhesion molecule is ICAM-1.
21. A method according to any one of claims 18 to 20 wherein the virus recognises the cell adhesion molecule for infectivity of the melanoma cells.
22. A method according to any one of claims 18 to 21 wherein the virus recognises 10 both the cell adhesion molecule and the complement regulatory protein for infectivity of the melanoma cells.
23. A method according to claim 18 wherein the virus recognises the complement regulatory protein for infectivity of the melanoma cells.
24. A method according to claim 22 or 23 wherein the complement regulatory protein 15 is DAF.
25. A method according to any one of claims 18 to 24 wherein the virus is an animal RNA virus.
26. A method according to any one of claims 18 to 25 wherein the virus is a member of the Picornaviridae family. 20
27. A method according to any one of claims 18 to 26 wherein the virus is a Coxsackivirus.
28. A method according to claim 27 wherein the virus is selected from the group consisting of CAV-13, CAV-15, CAV-18 and CAV-21. WO 01/37866 PCT/AUOO/01461 -43
29. A method according to any one of claims 18 to 28 wherein the virus is administered intravenously, intratumorally, intraperitoneally, intramuscularly, or by topical application.
30. A method according to claim 29 wherein the virus is administered by injection. 5
31. A method according to any one of claims 18 to 30 wherein the virus is administered to the patient in a dosage greater than about 1xlO2 plaque forming units per ml of innoculant.
32. A method according to claim 31 wherein the virus is administered to the patient in a dosage of between about 1x102 to 1x10O plaque forming units per ml of the 10 innoculant.
33. A method of screening abnormal cells for determining whether the cells are susceptible to viral induced cell death, comprising the steps of: (a) providing the abnormal cells; (b) adding to the cells an effective amount of a virus which recognises at least one 15 of a cell adhesion molecule of the immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells; (c) incubating the abnormal cells in the presence of the virus for a period of time; and (d) determining whether the virus has infected and caused death of at least some 20 of the abnormal cells.
34. A method according to claim 33 wherein the cell adhesion molecule is ICAM-1. WO 01/37866 PCT/AUOO/01461 - 44
35. A method according to claim 33 or 34 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of the abnormal cells.
36. A method according to claim 33 wherein the virus recognises the complement 5 regulatory protein for infectivity of the abnormal cells.
37. A method according to claim 35 or 36 wherein the complement regulatory protein is DAF.
38. A method according to any one of claims 33 to 37 wherein expression of the cell adhesion molecule is upregulated on the abnormal cells relative to normal said cells 10 expressing their normal phenotype.
39. A method according to any one of claims 33 to 37 wherein expression of the cell adhesion molecule is upregulated on the abnormal cells relative to cells of surrounding tissue in which the abnormal cells are found.
40. A method according to any one of claims 33 to 39 wherein the virus is an animal 15 RNA virus.
41. A method according to any one of claims 33 to 40 wherein the virus is a member of the Picornaviridae family.
42. A method according to any one of claims 33 to 41 wherein the virus is an Enterovirus. 20
43. A method according to claim 42 wherein the virus is a Coxsackievirus.
44. A method according to any one of claims 33 to 43 wherein the abnormal cells are cells of a malignancy selected from the group consisting of a malignancy of the skin, prostate cancer, stomach cancer, breast cancer and colon cancer. WO 01/37866 PCT/AUOO/01461 -45
45. A method of screening melanoma cells for determining whether the cells are susceptible to viral induced cell death, comprising the steps of: (a) providing the melanoma cells; (b) adding to the melanoma cells an effective amount of a virus which recognises 5 at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells; (c) incubating the melanoma cells in the presence of the virus for a period of time; and (d) determining whether the virus has infected and caused death of at least some 10 of the melanoma cells.
46. A method according to claim 45 wherein the cell adhesion molecule is a member of the immunoglobulin (Ig) super family.
47. A method according to claim 46 wherein the cell adhesion molecule is ICAM-1.
48. A method according to any one of claims 45 to 47 wherein the virus recognises the 15 cell adhesion molecule for infectivity of the melanoma cells.
49. A method according to any one of claims 45 to 48 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of the melanoma cells.
50. A method according to claim 45 wherein the virus recognises the complement 20 regulatory protein for infectivity of the melanoma cells.
51. A method according to any one of claims 45 to 50 wherein the complement regulatory protein is DAF. WO 01/37866 PCT/AUOO/01461 - 46
52. A method according to any one of claims 45 to 51 wherein the virus is a member of the Picornaviridae family.
53. A method according to claim 52 wherein the virus is an Enterovirus.
54. A method according to claim 53 wherein the virus is a Coxsackievirus. 5
55. A method of screening a virus for ability to infect and cause death of abnormal cells, comprising the steps of: (a) selecting a virus which recognises at least one of a cell adhesion molecule of the (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells; 10 (b) incubating the selected said virus with a sample of the abnormal cells for a period of time; and (c) determining whether the selected said virus causes death of at least some of the abnormal cells.
56. A method according to claim 55 further comprising comparing the ability of the 15 virus to infect and cause the death of the abnormal cells with that of a different said virus subjected to steps (b) and (c) utilising another sample of the cells.
57. A method according to claim 55 or 56 wherein the cell adhesion molecule is ICAM-1.
58. A method according to any one of claims 55 to 57 wherein the virus recognises the 20 cell adhesion molecule for infectivity of the abnormal cells.
59. A method according to any one of claims 55 to 58 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of the abnormal cells. WO 01/37866 PCT/AUOO/01461 - 47
60. A method according to claim 55 wherein the virus recognises the complement regulatory protein for infectivity of the abnormal cells.
61. A method according to claim 59 or 60 wherein the complement regulatory protein is DAF. 5
62. A method according to any one of claims 55 to 61 wherein expression of the cell adhesion molecule is upregulated on the abnormal cells relative to normal said cells expressing their normal phenotype.
63. A method according to any one of claims 55 to 62 wherein the virus is an animal RNA virus. 10
64. A method according to any one of claims 55 to 63 wherein the virus is a member of the Picornaviridae family.
65. A method according to claim 64 wherein the virus is a Coxsackievirus.
66. A method according to any one of claims 55 to 59 wherein the abnormal cells are cells of a malignancy selected from the group consisting of a malignancy of the skin, 15 prostrate cancer, stomach cancer, breast cancer and colon cancer.
67. A method of screening a virus for ability to infect and cause death of melanoma cells, comprising the steps of: (a) selecting a virus which recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells; 20 (b) incubating the selected said virus with a sample of the melanoma cells for a period of time; and (c) determining whether the selected said virus causes death of at least some of the melanoma cells. WO 01/37866 PCT/AUOO/01461 - 48
68. A method according to claim 67 further comprising comparing the ability of the virus to infect and cause the death of the melanoma cells with that of a different said virus subjected to steps (b) and (c) utilising another sample of the cells.
69. A method according to claim 67 or 68 wherein the cell adhesion molecule is a 5 member of the immunoglobulin (Ig) superfamily.
70. A method according to any one of claims 67 to 69 wherein the cell adhesion molecule is ICAM-1.
71. A method according to any one of claims 67 to 69 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of 10 the melanoma cells.
72. A method according to claim 67 or 68 wherein the virus recognises the complement regulatory protein for infectivity of the melanoma cells.
73. A method according to claim 71 or 72 wherein the complement regulatory protein is DAF. 15
74. A method according to any one of claims 67 to 73 wherein the virus is an animal RNA virus.
75. A method according to any one of claims 67 to 74 wherein the virus is a member of the Picornaviridae family.
76. A method according to claim 75 wherein the virus is an Enterovirus. 20
77. A method according to claim 76 wherein the virus is a Coxsackievirus.
78. A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a virus capable of infecting abnormal cells whereby death of the cells is caused and which recognises at least one of a cell adhesion molecule of the WO 01/37866 PCT/AUOO/01461 - 49 immunoglobulin (Ig) superfamily and a complement regulatory protein for infectivity of the abnormal cells.
79. A pharmaceutical composition according to claim 78 wherein the cell adhesion molecule is ICAM-1. 5
80. A pharmaceutical composition according to claim 78 or 79 wherein the virus recognises the cell adhesion molecule for infectivity of the abnormal cells.
81. A pharmaceutical composition according to any one of claims 78 to 80 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of the abnormal cells. 10
82. A pharmaceutical composition according to claim 78 wherein the virus recognises the complement regulatory protein for infectivity of the abnormal cells.
83. A pharmaceutical composition according to claim 82 wherein the complement regulatory protein is DAF.
84. A pharmaceutical composition according to any one of claims 78 to 81 wherein 15 expression of the cell adhesion molecule is upregulated on the abnormal cells relative to normal said cells expressing their normal phenotype.
85. A pharmaceutical composition according to any one of claims 78 to 84 wherein the virus is an animal RNA virus.
86. A pharmaceutical composition according to any one of claims 78 to 85 wherein the 20 virus is a member of the Picornaviridae family.
87. A pharmaceutical composition according to claim 86 wherein the virus is an Enterovirus. WO 01/37866 PCT/AUOO/01461 - 50
88. A pharmaceutical composition according to claim 87 wherein the virus is a Coxsackievirus.
89. A pharmaceutical composition according to any one of claims 78 to 88 wherein the abnormal cells are malignant cells of a malignancy selected frrnthe group consisting of 5 a malignancy of the skin, prostrate cancer, stomach cancer, breast cancer and colon cancer.
90. A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a virus capable of infecting melanoma cells whereby death of the cells is caused and which recognises at least one of a cell adhesion molecule and a complement 10 regulatory protein for infectivity of the melanoma cells.
91. A pharmaceutical composition according to claim 90 wherein the cell adhesion molecule is a member of the immunoglobulin (Ig) superfamily.
92. A pharmaceutical composition according to claim 90 or 91 wherein the cell adhesion molecule is ICAM-1. 15
93. A pharmaceutical composition according to any one of claims 90 to 92 wherein the virus recognises the cell adhesion molecule for infectivity of the melanoma cells.
94. A pharmaceutical composition according to any one of claims 90 to 93 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of the melanoma cells. 20
95. A pharmaceutical composition according to claim 90 wherein the virus recognises the complement regulatory protein for infectivity of the melanoma cells.
96. A pharmaceutical composition according to claim 95 wherein the complement regulatory protein is DAF. WO 01/37866 PCT/AUOO/01461 -51
97. A pharmaceutical composition according to any one of claims 90 to 96 wherein the virus is an animal RNA virus.
98. A pharmaceutical composition according to any one of claims 90 to 97 wherein the virus is a member of the Picornaviridae family. 5
99. A pharmaceutical composition according to claim 98 wherein the virus is an Enterovirus.
100. A pharmaceutical composition according to claim 99 wherein the virus is a Coxsackievirus.
101. A pharmaceutical composition according to claim 100 wherein the Coxsackievirus 10 is selected form the group consisting of CAV- 13, CAV-15, CAV- 18 and CAV-2 1.
102. A delivery means for being held against the skin of a patient and which is impregnated with a pharmaceutical composition as defined in any one of claims 78 to 101 for contact with the skin.
103. A delivery means according to claim 102 comprising a patch, pad, wad or bandage. 15
104. A delivery means according to claim 102 or 103 adapted for sticking to the skin of the patient to thereby hold the pharmaceutical composition in contact with the skin.
105. Use of a virus capable of infecting abnormal cells whereby death of the cells is caused, in the manufacture of a medicament for treating the abnormal cells and wherein the virus recognises at least one of a cell adhesion molecule of the immunoglobulin (Ig) 20 superfamily and a complement regulatory protein for infectivity of the abnormal cells.
106. Use according to claim 105 wherein the virus recognises ICAM-1 for infectivity of the abnormal cells. WO 01/37866 PCT/AUOO/01461 - 52
107. Use according to claim 105 or 106 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of the abnormal cells.
108. Use according to claim 105 wherein the virus recognises the complement 5 regulatory protein for infectivity of the abnormal cells.
109. Use according to claim 107 or 108 wherein the complement regulatory protein is DAF.
110. Use according to any one of claims 105 to 107 wherein expression of the cell adhesion molecule is upregulated on the abnormal cells relative to non-malignant said 10 cells expressing their normal phenotype.
111. Use according to any one of claims 105 to 107 wherein expression of the cell adhesion molecule is upregulated on the abnormal cells relative to cells of surrounding tissue in which the abnormal cells are found.
112. Use according to any one of claims 105 to 111 wherein the virus is an animal RNA 15 virus.
113. Use according to any one of claims 105 to 112 wherein the virus is a member of the Picornaviridae family.
114. Use according to claim 113 wherein the virus is an Enterovirus.
115. Use according to claim 114 wherein the virus is a Coxsackievirus. 20
116. Use according to claim 115 wherein the virus is selected from the group consisting of CAV-13, CAV-15, CAV-18 and CAV-21. WO 01/37866 PCT/AUOO/01461 - 53
117. Use according to any one of claims 105 to 115 wherein the abnormal cells are cells of a malignancy selected from the group consisting of a malignancy of the skin, prostrate cancer, stomach cancer, breast cancer and colon cancer.
118. Use of a virus capable of infecting melanoma cells whereby death of the cells is 5 caused, in the manufacture of a medicament for treating melanoma and wherein the virus recognises at least one of a cell adhesion molecule and a complement regulatory protein for infectivity of the melanoma cells.
119. Use according to claim 118 wherein the cell adhesion molecule is a member of the immunoglobulin (Ig) superfamily. 10
120. Use according to claim 118 or 119 wherein the cell adhesion molecule is ICAM-1.
121. Use according to any one of claims 118 to 120 wherein the virus recognises the cell adhesion molecule for infectivity of the melanoma cell.
122. Use according to any one of claims 118 to 121 wherein the virus recognises both the cell adhesion molecule and the complement regulatory protein for infectivity of the 15 melanoma cells.
123. Use according to claim 118 wherein the virus recognises the complement regulatory protein for infectivity of the melanoma cells.
124. Use according to claim 122 or 123 wherein the complement regulatory protein is DAF. 20
125. Use according to any one of claims 118 to 124 wherein the virus is an animal RNA virus.
126. Use according to any one of claims 118 to 125 wherein the virus is a member of the Picornaviridae family. WO 01/37866 PCT/AUOO/01461 - 54
127. Use according to claim 125 or 126 wherein the virus is an Enterovirus.
128. Use according to claim 127 wherein the virus is a Coxsackievirus.
129. Use according to claim 128 wherein the virus is selected from the group consisting of CAV-13, CAV-15, CAV-18 and CAV-21.
AU16816/01A 1999-11-25 2000-11-27 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same Ceased AU770517B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU16816/01A AU770517B2 (en) 1999-11-25 2000-11-27 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292A AU2004202292B2 (en) 1999-11-25 2004-05-26 Method of Treating a Malignancy in a Subject

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ4256A AUPQ425699A0 (en) 1999-11-25 1999-11-25 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AUPQ4256 1999-11-25
PCT/AU2000/001461 WO2001037866A1 (en) 1999-11-25 2000-11-27 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU16816/01A AU770517B2 (en) 1999-11-25 2000-11-27 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004202292A Division AU2004202292B2 (en) 1999-11-25 2004-05-26 Method of Treating a Malignancy in a Subject

Publications (2)

Publication Number Publication Date
AU1681601A true AU1681601A (en) 2001-06-04
AU770517B2 AU770517B2 (en) 2004-02-26

Family

ID=31979093

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16816/01A Ceased AU770517B2 (en) 1999-11-25 2000-11-27 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same

Country Status (1)

Country Link
AU (1) AU770517B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Also Published As

Publication number Publication date
AU770517B2 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
US8722036B2 (en) Methods for treating malignancies using coxsackieviruses
AU2005221725B2 (en) Modified oncolytic viruses
US8236298B2 (en) Methods and compositions for treatment of hematologic cancers
NZ541230A (en) A method of treating abnormal cells in a non-human mammal using a echovirus which recognise alpha-1 beta-2 for infecitvity of the cells
AU770517B2 (en) A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) Method of Treating a Malignancy in a Subject
AU2015230743A1 (en) A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2007211890A1 (en) A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2005274617B2 (en) Methods and compositions for treatment of hematologic cancers

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VIROTARG PTY LIMITED

Free format text: THE FORMER OWNER WAS: THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired